pirenzepine has been researched along with Lymphoproliferative Disorders in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Polloni, A | 1 |
| Marchi, S | 1 |
| Martire, A | 1 |
| Costa, F | 1 |
| Cecconi, N | 1 |
| Ruocco, L | 1 |
| Maltinti, G | 1 |
| Grassi, B | 1 |
| Del Tacca, M | 1 |
1 trial available for pirenzepine and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Pirenzepine versus ranitidine in gastroprotection during antiblastic chemotherapy: a double-blind study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Duodenum; Female; Gastri | 1986 |